TARS vs CRSP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TARS · Tarsus Pharmaceuticals$73.01 ▼ 6.00%
CRSP · CRISPR Therapeutics$39.10 ▲ 0.44%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TARS -11.1%
- CRSP -23.7%
Head to head
| Metric | TARS | CRSP |
|---|---|---|
| Price | $73.01 | $39.10 |
| Change today | ▼ 6.00% | ▲ 0.44% |
| Market cap | $3.60B | $3.79B |
| Return, 3 months | +0.3% | -31.5% |
| Return, year to date | -10.8% | -25.4% |
| Return, 1 year | -8.3% | -22.2% |
| P/E (TTM) | – | – |
| P/B | 34.6 | 2.3 |
| P/E percentile vs own 5y | 90th | 53rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +63.9% | +1,325.1% |
| Net profit growth (YoY) | -5,210.6% | -4.7% |
| Gross margin | 93.2% | -676.9% |
| Operating margin | -102.3% | -2,221.7% |
| Net margin | -102.9% | -1,955.7% |
| Return on equity | -319.8% | -25.6% |
| Analyst target vs. price | +44.6% | +89.9% |
| Analyst buy share | 100% | 67% |
| RSI (14) | 48 | 28 |
| 30-day volatility | 48.8% | 56.0% |
| Max drawdown, 1 year | -32.0% | -37.1% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CRSP is the largest of the group by market value.
- TARS has returned the most over the past year.
- CRSP is growing revenue fastest.
- TARS keeps the most profit per dollar of sales.
- TARS has been the calmest stock over the last 30 days.